Literature DB >> 8782350

Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2.

S Corbeil1, C Seguin, M Trudel.   

Abstract

Passive immunization of mice with 131 micrograms of the non-neutralizing monoclonal antibody (mAb) 18A2B2, directed against the A subgroup epitope of the G glycoprotein of respiratory syncytial virus Long strain (RSV), confers protection against viral i.n. challenge. The role of the Fc fragment of this antibody as well as the involvement of antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis towards protection was evaluated in vivo. Passive immunization with the Fab fragment alone (618-907 micrograms mouse-1) was unable to confer protection in mice. Furthermore, we passively immunized with the mAb 18A2B2 SCID beige mice, which are deficient in natural killer (NK) cell activity, to ascertain the role of NK cells in the protective mechanism. These mice were free of virus 5 days following viral challenge, indicating that NK cells do not contribute significantly towards the protective action of this antibody. Moreover, passively immunized BALB/c mice decomplemented with 8-10 U of cobra venom factor (CoVF) and DBA/2J mice (C5 deficient) were only partially protected. These findings suggest that in mice the alternative and classical pathways of the complement system are involved in the passive protection mechanism conferred by the non-neutralizing mAb 18A2B2. To our knowledge, it is the first description of a protective mechanism in mice that involves a non-neutralizing antibody and the complement system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782350      PMCID: PMC7126533          DOI: 10.1016/0264-410x(95)00222-m

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect.

Authors:  J C Roder; M L Lohmann-Matthes; W Domzig; H Wigzell
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

2.  Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization.

Authors:  M Trudel; F Nadon; C Séguin; P Payment; P J Talbot
Journal:  Can J Microbiol       Date:  1987-10       Impact factor: 2.419

3.  The beige mutation in the mouse selectively impairs natural killer cell function.

Authors:  J Roder; A Duwe
Journal:  Nature       Date:  1979-03-29       Impact factor: 49.962

4.  Protective and disease-enhancing immune responses to respiratory syncytial virus.

Authors:  L J Anderson; C A Heilman
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

5.  Protection from lethal coronavirus infection by immunoglobulin fragments.

Authors:  A Lamarre; P J Talbot
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

6.  Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus.

Authors:  E Norrby; M A Mufson; H Alexander; R A Houghten; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

7.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.

Authors:  L J Anderson; P Bingham; J C Hierholzer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Evaluation of protocols for purification of mouse monoclonal antibodies. Yield and purity in two-dimensional gel electrophoresis.

Authors:  L Manil; P Motté; P Pernas; F Troalen; C Bohuon; D Bellet
Journal:  J Immunol Methods       Date:  1986-06-10       Impact factor: 2.303

10.  The morphology of virus-antibody interaction.

Authors:  J D Almeida; A P Waterson
Journal:  Adv Virus Res       Date:  1969       Impact factor: 9.937

View more
  15 in total

1.  Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.

Authors:  F Verrier; A Nádas; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

Authors:  H Sakurai; R A Williamson; J E Crowe; J A Beeler; P Poignard; R B Bastidas; R M Chanock; D R Burton
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 3.  Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.

Authors:  Bahaa Abu-Raya; Frederic Reicherz; Pascal M Lavoie
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-11       Impact factor: 8.667

4.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

5.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Authors:  Congrong Miao; Gertrud U Radu; Hayat Caidi; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

8.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

9.  Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases.

Authors:  Hyo-Jeong Lee; Jeong-Yoon Lee; Min-Hee Park; Joo-Young Kim; Jun Chang
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

Review 10.  In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus.

Authors:  Joo Young Kim; Jun Chang
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.